May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Comparing Definitions of Glaucoma Progression in the Glaucoma Longitudinal Imaging Study (GILS)
Author Affiliations & Notes
  • H. D. Jampel
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • S. Vitale
    Division of Epidemiology and Clinical Research, National Eye Institute, NIH, Bethesda, Maryland
  • M. Boland
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • N. G. Strouthidis
    Glaucoma Research Unit, Moorfields Eye Hospital, London, United Kingdom
  • D. F. Garway-Heath
    Glaucoma Research Unit, Moorfields Eye Hospital, London, United Kingdom
  • R. Zeimer
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • F. Knezevich
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Y. Ding
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • D. Friedman
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • H. Quigley
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  H.D. Jampel, None; S. Vitale, None; M. Boland, None; N.G. Strouthidis, None; D.F. Garway-Heath, Heidelberg Engineering, Carl Zeiss Meditec, Optovue, F; CZM, Carl Zeiss Meditec, C; R. Zeimer, Retinal Thickness Analyzer, P; F. Knezevich, None; Y. Ding, None; D. Friedman, Carl Zeiss Meditec, Heidelberg Engineering, F; H. Quigley, Carl Zeiss Meditec, C.
  • Footnotes
    Support  R01 EY-12295-03
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1592. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. D. Jampel, S. Vitale, M. Boland, N. G. Strouthidis, D. F. Garway-Heath, R. Zeimer, F. Knezevich, Y. Ding, D. Friedman, H. Quigley; Comparing Definitions of Glaucoma Progression in the Glaucoma Longitudinal Imaging Study (GILS). Invest. Ophthalmol. Vis. Sci. 2008;49(13):1592. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To determine which eyes in the Glaucoma Imaging Longitudinal Study (GILS) demonstrated progressive damage.

 
Methods:
 

The GILS followed a cohort of established glaucoma patients with definite visual field (VF) and optic disc damage every 6 months using Humphrey 24-2 SITA Fast VF and the Heidelberg Retina Tomograph 2 (HRT2). Eyes with a minimum of ≥5 high quality Humphrey 24-2 SITA fast visual fields amenable to GPA analysis and ≥ 4 Heidelberg Retina Tomograph 2 (HRT 2) studies were evaluated for glaucomatous progression, defined as Glaucoma Progression Analysis (GPA) classification of "possible" or "likely", or significant sector rim thinning determined by HRT2.

 
Results:
 

115 eyes of 84 subjects (from 312 eyes of 205 subjects in the GILS) met the inclusion criteria. The mean ± standard deviation follow up was 39 ± 7 (range 22 to 52) months. Thirty-two eyes of 28 subjects progressed, 21 by HRT 2 criteria (mean time to progression 16.3 ± 11.9 months), and 19 by GPA visual field criteria (7 "likely" and 12 "possible", mean time to progression 29.3 ± 5.3 and 31.0 ± 7.9 months, respectively). Five eyes were classified as "improved" by HRT 2 criteria (GPA does not have an "improved" classification).

 
Conclusions:
 

In this cohort of eyes with established glaucomatous visual field loss at the outset, approximately equal number of eyes progressed by either disc or field criteria, but few eyes progressed by both. With the specific criteria for progression that we chose, progression was detected earlier in general by HRT2. Depending upon the criteria chosen, the crude progression rate in this cohort ranges from approximately 1% (HRT2 plus GPA likely) to 9% annually (either HRT2 or GPA or both).  

 
Keywords: imaging/image analysis: clinical • perimetry • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×